When there is no single best biological agent: Psoriasis and psoriatic arthritis in the same patient responding to two different biological agents

Clinical and Experimental Dermatology

Volumn 33, Issue 2, 2008, Pages 164-166

  Adisen E ^a   Karaca, F ^a   Gurer M A ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; METHOTREXATE;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERPHALANGEAL JOINT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SKIN DEFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 38849141618     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2007.02673.x     Document Type: Article

References (14)

1. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 97.
2. Papp KA, Miller B, Gordon KB et al. Efalizumab Study Group. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006 54 : S164 70.
3. Lowes MA, Turton JA, Krueger JG, Barnetson RS. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol 2005 18 : 5 9.
4. Carey W, Glazer S, Gottlieb AB et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006 54 : S171 81.
5. Papp KA, Ho V, Langley R et al. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. J Cutan Med Surg 2006 9 : 26 32.
6. Menter A, Hamilton TK, Toth DP et al. Transitioning patients from efalizumab to alternative psoriasis therapies: finding from an open-label, multicenter, phase IIIb study. Int J Dermatol 2007 46 : 637 48.
7. Bang B, Gniadecki R. Severe exacerbation of psoriatic arthritis during treatment with efalizumab. A case report. Acta Derm Venereol 2006 86 : 456 7.
8. Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol 2006 54 : S85 91.
9. Mease P, Gladman D, Ritchlin C et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005 52 : 3279 89.
10. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004 50 : 2264 72.
11. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005 64 : 1150 7.
12. Reich K, Nestle FO, Papp K et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 74.
13. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: doubleblind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 55 : 598 606.
14. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003 139 : 1627 32.